Alex is an immunologist with broad and long-standing experience in basic research, pre-clinical model development and translational research to understand the immune response and its associated inflammation in various pathological contexts (i.e. infectious diseases, cancer).
At insitro, Alex is a Sr. Scientist in the translational assay group helping guide the team with a focus on identifying and validating intermediate phenotypes of disease processes. She is working in close collaboration with the genetic, disease modeling, process engineering and machine learning modules of insitro to accelerate and scale-up the interpretation of the output.
Prior to joining insitro, Alex transitioned from academia to Biopharma in 2017 as a Senior Scientific Researcher at Genentech in the Cancer Immunology department. She implemented translational tools with the aim of accelerating biomarker discovery in the context of immune checkpoint interventions. Additionally, Alex was a biological lead for the development of small/biological molecules in the space of anti-tumor immunity.
Alex was born in Paris, France and received her Ph.D. in Immunology and Physiopathology from the University Pierre et Marie Curie at the Institut Pasteur where she developed a standardized and high-throughput workflow for transcriptomic analysis of a syringe-based whole blood stimulation system to support the population-based integrative approach of the “Milieu Interieur” consortium.
In her free time, Alex enjoys listening to music, dancing, trying out new cuisines and exploring the outside world with her kids.
Ariel Kauss is a cell biologist with expertise in fibrosis and cardiac biology, utilizing both developmental and bioengineering approaches. At insitro, she will focus on validating potential targets for fibrosis and NASH.
Prior to insitro, Ariel was a Research Scientist in FibroGen’s Cell Biology department, and was heavily involved in early research with large and small molecules targeting fibrosis and cancer. Ariel received her Bachelor’s Degree from Cornell University, and then worked at both City of Hope and Genentech researching gene therapy and cardiotoxicity before returning to graduate school. She received her PhD from UCSF, where she was co-advised by Todd McDevitt and Deepak Srivastava in the Gladstone Institute of Cardiovascular Disease. Her thesis focused on reproducing age-specific cardiac extracellular matrix in vitro to facilitate the identification of matrix proteins that impact cardiac regeneration.
In her free time, Ariel enjoys Zumba and beach days.
Atieh is a scientist with the translation science team where she focuses on designing and developing cellular and molecular assays to find relevant disease phenotypes.
Prior to insitro, she worked at IDEAYA Biosciences and had a role in developing and running high throughput cellular screening assays that helped with the discovery of the company’s first internal synthetic lethality clinical candidate.
Atieh has a background in Biotechnology and received her B.S. from the University of California, Davis followed by a Professional Science Masters degree in the same field from University of San Francisco.
While not working, Atieh enjoys tackling DIY projects, hiking different trails in the bay area, watching soccer tournaments, and spending time with her family and friends.
__Kelly Haston is a stem cell biologist with broad experience in human stem cell-based models of development and disease. She is a Sr. Scientist in the biology and translational genetics group helping guide the team as they build biological model systems that will interface with the genetic, data science and machine learning modules of insitro’s unique approach to discover novel human therapeutics.
Kelly was born in Ottawa and grew up in central British Columbia and Toronto, Canada. She did her undergraduate and masters work at the UC Berkeley studying the effects of pesticides on frog gonad development. She then began working in the stem cell field during her Ph.D. with Dr. Renee Rejio Pera at UC San Francisco and Stanford University. Kelly performed postdoctoral positions briefly with Dr. Lee Rubin at Harvard and then with Dr. Steven Finkbeiner at UCSF’s Gladstone Institutes where she focused on building stem cell based models of neurodegeneration. She transitioned to industry in 2017, taking a position with a small start up, Scaled Biolabs, as Lead Scientist where she used the company’s novel discovery platform to optimize the production of many different cell types from human stem cells.
Kelly uses her spare time to be outside as much as possible, mainly trail running or fastpacking. She also loves reading, traveling to new places and attending live music and performances.
—Lorn Kategaya is a cell biologist with small molecule drug discovery experience. At insitro, Lorn will develop relevant disease assays and utilize genetic/chemical screens to identify key biological players that modulate disease outcomes.
Lorn has a PhD in pharmacology from the University of Washington, a post-doc from UCSF and industry experience at Genentech and IDEAYA Biosciences.
Away from the bench, Lorn follows politics and enjoys live music, theatrical performances, and french fries.
Werner Syndrome Helicase is Required for the Survival of Cancer Cells with Microsatellite Instabilityhttps://www.cell.com/iscience/fulltext/S2589-0042(19)30040-9
USP7 small-molecule inhibitors interfere with ubiquitin bindinghttps://www.nature.com/articles/nature24006
Matthew Albert, SVP of Biology & Translational Genetics
SVP, Biology & Translational Genetics
Matthew Albert, SVP of Biology & Translational Genetics
Matthew Albert is Senior Vice President, Biology & Translational Genetics at insitro.
Prior to joining insitro, Matthew worked as Principal Scientist in the Department of Cancer Immunology at Genentech (2015 – 2019); and served as Professor (2003 – 2015), Founder and Director of the Center for Human Immunology (2007 – 2015) and Director of the Immunology Department at Institut Pasteur, Paris France (2010 – 2015).
Matthew is an immunologist and clinical pathologist, with a long-standing interest in immune regulation and tumor immunity. His research embraces the power of a “human-first” approach to scientific discovery, driven by a commitment to understand how to achieve effective response to cancer immunotherapy, autoimmunity and chronic infection while limiting adverse effects of treatment. As this requires a deep insight into health and disease pathogenesis, he has developed several areas of investigation over the last two decades, which has included a deep commitment to bladder diseases (incl. cancer and UTI); and liver diseases (incl. HCV, HBV, HCC and NASH). He has also been a leader in the Milieu Intérieur Consortium, a 30-team academic / industrial partnership that aims to define the genetic, microbiome and environmental determinants of variable immune responses in healthy persons.
Matthew trained at The Rockefeller University, Cornell University Medical College and did his residency at New York Presbyterian Hospital. He is the author of more than 100 peer-reviewed scientific papers and has made major contributions to the understanding of antigen cross-priming and the impact of post-translational modification of chemokines as determinants of effective tumor immunity. In his spare time, he and his family enjoy cooking together, traveling and exploring the world’s ecology under the sea (marvelling at Ostracod mating practices in the Carribean), in jungles (visits to the Sarawak Biodiversity Centre in Borneo), and in ecology parks (riding dolphins in Tunisia). The have traveled together to over 35 countries, with a strong belief that knowing and engaging with diverse communities and cultures help them be better contributors to the world.
Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T, Khan Z, Mariathasan S, Daemen A, Reeder J, Haverty PM, Forrest WF, Brauer M, Mellman I, Albert ML. Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11701-E11710. doi: 10.1073/pnas.1804506115. Epub 2018 Nov 21
Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, Alanio C, Scepanovic P, Hammer C, Jönsson F, Beitz B, Quach H, Lim YW, Hunkapiller J, Zepeda M, Green C, Piasecka B, Leloup C, Rogge L, Huetz F, Peguillet I, Lantz O, Fontes M, Di Santo JP, Thomas S, Fellay J, Duffy D, Quintana-Murci L, Albert ML; Milieu Intérieur Consortium. Nat Immunol. 2018 Mar;19(3):302-314. doi: 10.1038/s41590-018-0049-7. Epub 2018 Feb 23
Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. Quach H, Rotival M, Pothlichet J, Loh YE, Dannemann M, Zidane N, Laval G, Patin E, Harmant C, Lopez M, Deschamps M, Naffakh N, Duffy D, Coen A, Leroux-Roels G, Clément F, Boland A, Deleuze JF, Kelso J, Albert ML, Quintana-Murci L. Cell. 2016 Oct 20;167(3):643-656.e17. doi: 10.1016/j.cell.2016.09.024
Google scholarView articles
Rahul is a biomedical engineer, with advanced expertise in the design and execution of complex phenotypic cell-based assays, directly supporting the development of cutting-edge screening paradigms for novel target discovery for neurodegenerative disorders. As a scientist in the Department of Biology and Translational Genetics, Rahul supports insitro’s therapeutic strategies in neuroscience-related indications in collaboration with company leaders.
Prior to joining insitro, Rahul was part of a Stealth Biotech startup in the Bay area and led cell-based screening efforts as the lead assay development scientist in the oncology space.
Rahul received his bachelor’s degree in Biomedical Sciences at Southeast Missouri State University. He received his PhD in Bioengineering at the University of Texas at Dallas, under the tutelage of Dr. Joseph Pancrazio, where he developed a DRG sensory neuron-based phenotypic screening assay to discover non-opioid therapeutics for the treatment of chronic pain to support the NIH HEAL initiative, an aggressive, trans agency effort to mitigate the national opioid health crisis.
In his free time, Rahul enjoys going on walks with a friend, playing with his Bichon Frise Nova, and not finishing jigsaw puzzles.
Adaptation of robust Z’factor for assay quality assessment in microelectrode array based screening using adult dorsal root ganglion neurons.https://www.sciencedirect.com/science/article/abs/pii/S0165027020301229
Adult mouse sensory neurons on microelectrode arrays exhibit increased spontaneous and stimulus-evoked activity in the presence of interleukin-6.https://journals.physiology.org/doi/full/10.1152/jn.00158.2018
Conserved expression of Nav1.7 and Nav1.8 contribute to the spontaneous and thermally evoked excitability in IL-6 and NGF-sensitized adult dorsal root ganglion neurons in vitro.https://www.mdpi.com/2306-5354/7/2/44
KeywordsBiology and Translational Genetics,
Rob is a Scientist I, Flow Cytometry Specialist whose primary responsibilities is to lead projects focused on flow-based phenotyping and cell sorting within a high-throughput drug screening platform. He defines the needs for cross-functional workflows to establish and execute processes that will enable insitro’s iPSCs platform to operate successfully with regard to cell management and screening. This role is highly collaborative with a talented multidisciplinary team to develop cutting-edge activities in a state-of-the-art environment with the aim to accelerate machine learning based drug discoveries. Additional responsibilities include close partnership with our data and process engineering teams to drive the integration of cytometry-based protocols into semi-automated pipelines.
Prior to joining Insitro Rob was a flow cytometry application scientist with Miltenyi Biotec and prior to that he was at John’s Hopkins University where he earned a M.S. in Biotechnology. He expanded his time at John’s Hopkins University to work as a researcher in an infectious disease laboratory focused on bacterial infections primarily within the skin and bones under the supervision of Lloyd Miller M.D., Ph.D.
In his free time Rob enjoys outdoor activities that includes biking, surfing, snowboarding, camping and cooking for friends and family.
Google scholarView articles
Tima is a biomedical engineer with wide-ranging expertise in inflammation, vascular dysfunction, fibrosis, and drug development. As a Scientist on the fibrosis team, she develops cellular and molecular assays to identify and validate disease phenotypes and therapeutic targets for chronic fibrotic diseases.
Tima graduated with her B.S. in Physiological Sciences from the University of California, Los Angeles before working in a plastic surgery research lab at the UC Davis Medical Center, where she studied the oncogenic risk of stem cell-enriched fat grafting during breast augmentation in post-mastectomy patients. She received her PhD in Biomedical Engineering from the University of California, Davis, where she developed targeted macromolecules to protect the vasculature from acute inflammatory damage.
Outside of the lab, Tima enjoys hiking, ski touring and downhill skiing, and trying out different coffee shops.
KeywordsBiology and Translational Genetics,
Yuchin is a cell biologist with small molecule and biologic drug development experience. At insitro, she will contribute to the building of 2D and 3D cell models of disease and causal processes.
She received her B.A. in Molecular and Cell Biology from UC Berkeley and her industry experience focused on assay development, target validation, and mechanism of action studies.
In her free time, she enjoys traveling, gardening, eating, and doing arts and crafts.